MK-8776 (SCH 900776)

目录号:S2735

仅限科研使用

MK-8776 (SCH 900776)是一种选择性Chk1抑制剂,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。Phase 2。

MK-8776 (SCH 900776) Chemical Structure

CAS: 891494-63-6

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1921.21 现货
RMB 1733.35 现货
RMB 7966.05 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的MK-8776 (SCH 900776)发表文献55篇:

产品安全说明书

Chk抑制剂选择性比较

相关Chk产品

生物活性

产品描述 MK-8776 (SCH 900776)是一种选择性Chk1抑制剂,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。Phase 2。
靶点
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
3 nM 0.16 μM
体外研究

SCH 900776是Chk2和CDK2的低效抑制剂,IC50分别为1.5 μM 和 0.16 μM。SCH 900776对细胞色素P450人肝微粒体亚型1A2,2C9,2C19,2D6,和3A4没有显著的抑制作用。羟基脲下暴露24小时后,SCH 900776诱导DNA复制能力剂量依赖性损失。SCH 900776增强γ-H2AX对羟基脲,5-氟尿嘧啶,和阿糖孢苷的响应。与抗代谢物结合,SCH 900776在2小时内诱导γ-H2AX的累积,表明复制叉瓦解,并且双链DNA断裂。此外,SCH 900776以剂量依赖的方式抑制Chk1 pS296自磷酸化的积累。增殖的WS1细胞暴露于SCH 900776,与Chk1 pS345快速的,剂量依赖性聚集相关,表明正常细胞的循环群诱导Chk1 pS345在暴露于SCH 900776后,是一部分无效循环,这也许通过AT-家族激酶和DNA-PK驱动。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T6clIxOC9{MECwJI5O M{f5N|I1KGh? Mnrj[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n M1HRS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
HCT115 Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:3NlAxNzJyMECgcm0> NVLLO3RbOjRiaB?= M{C0fYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NHT0S4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
SW620 NHzaWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInBTo4zODBxMkCwNEBvVQ>? MXyyOEBp NGSzb5Zl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= MlO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
IGROV-1 NVL2RVNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rB[|IxOC9{MECwJI5O MVmyOEBp M170OYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MmjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
HCT116 NGq0bGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnKWFNNOjByL{KwNFAhdk1? NFz6bIozPCCq M4jTO4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
MCF10A M1j3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfUcYQzODBxMkCwNEBvVQ>? MorVNlQhcA>? MkfM[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NWSwPFM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
MiaPaCa-2 NH7K[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXeyNFAwOjByMDDuUS=> Mn7tNlQhcA>? MnPH[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
MDA-MB-231 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;oT|FCOjByL{KwNFAhdk1? MWCyOEBp MVTk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
HCC2998 M2LFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLkNlAxNzJyMECgcm0> M1fZfFI1KGh? NHSyVJdl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NWO4VXpZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
U87 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzpWYszODBxMkCwNEBvVQ>? NFf4TWszPCCq MorQ[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
MDA-MB-435 NVvv[ZdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDMNlAxNzJyMECgcm0> MVGyOEBp MmPH[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n M{PDfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
SNB19 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSxR44zODBxMkCwNEBvVQ>? NF\SUY4zPCCq NGHkeoJl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NVXjdppzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
U20S NHLVS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTqNlAxNzJyMECgcm0> MnfvNlQhcA>? MoTo[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NWPOUYVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
A498 NUfrb2RsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfTNlAxNzJyMECgcm0> MViyOEBp NX;mc4tj\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l M{HNdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
TK10 NVnMSHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqyNFAwOjByMDDuUS=> NW\XSo5kOjRiaB?= NXHySVRs\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
AsPC-1 M{GxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGzeIJEOjByL{KwNFAhdk1? NGG2b|IzPCCq MUfk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
H23 NVLoc|dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXW[JM1PTByIH7N MU[yOEBp NFvGfGlFVVOR M1O1XoVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzM{W0PUc,OjRzMUO1OFk9N2F-
H1437 NVfjTo5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf2THA2ODBibl2= MWSyOEBp M3jnSGROW09? NYnvfYxx\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{BRVVh? MoDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUO1OFkoRjJ2MUGzOVQ6RC:jPh?=
H1993 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnQV2dnPTByIH7N MmK0NlQhcA>? NX[yXYlDTE2VTx?= M2LtOIVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzM{W0PUc,OjRzMUO1OFk9N2F-
H1299 NFzlV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS1NFAhdk1? MVuyOEBp NHn4N3VFVVOR NF3FS5ZmdmijbnPld{B1cGViY3jlcY9{\W6|aYTpfoF1cW:wIITvJHBOYA>? NYq3RnhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNVM2PDlpPkK0NVE{PTR7PD;hQi=>
AsPC-1 NWD3OFBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXUPGk1OTBvMUCwNEBvVQ>? M{CxXlI1NTR6aB?= M3y2bIVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> NIj4WFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwOFQzOid-MkO4NFQ1OjJ:L3G+
MiaPaCa-2 M17JT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHzNVAuOTByMDDuUS=> NW\xdIk4OjRvNEjo M3G1TYVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> NGW4O|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwOFQzOid-MkO4NFQ1OjJ:L3G+
BxPC-3 M{W3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DWbFExNTFyMECgcm0> NFjyXngzPC12OHi= MnP1[Y5p[W6lZYOgeIhmKGOqZX3vd4Vve2m2aYrheIlwdiC2bzDn[Y1kcXSjYnnu[S=> NHP5VpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwOFQzOid-MkO4NFQ1OjJ:L3G+
SKOV3 NYDGUXNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKwMlMhyrWP M{TqU|gh\A>? MXvz[Y5{cXSrenXzJJRp\SClZXzsJIxqdmW|IITvJIdmdWOrdHHibY5myqB? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2OEK2PUc,OjN3NEiyOlk9N2F-
OVCAR-8 NYXLWlJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uxSFAvOyEEtV2= NHi5fIc5KGR? Mln3d4Vve2m2aYrld{B1cGViY3XscEBtcW6nczD0c{Bo\W2laYThZolv\cLi M4jvT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUS4NlY6Lz5{M{W0PFI3QTxxYU6=
MV-4-11 MoHSRZBweHSxc3nzJGF{e2G7 M3LpXFExOC15MECgcm0> NXnt[olyPDhiaB?= MkDRbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV|NkeyNUc,OjN3M{[3NlE9N2F-
U937 NX\6Z3VtSXCxcITvd4l{KEG|c3H5 NUT2fZpMOTByLUewNEBvVQ>? NHezd5c1QCCq NFrO[5BqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NEPNTHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzOlczOSd-MkO1N|Y4OjF:L3G+
MOLM-13  NHzncm1CeG:ydH;zbZMhSXO|YYm= M{TZNlExOC15MECgcm0> NX7NdppNPDhiaB?= MVrpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NEPCZ4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzOlczOSd-MkO1N|Y4OjF:L3G+
A2058  MojrR4VtdCCYaXHibYxqfHliQYPzZZk> NXjuOodnOzdwNT2zNFAhdk1? NITtfJQ4OiCq M3XQRWROW09? M4\lWZJm\HWlZYOgeIhmKE2NLUG3O|UhTUN3MNMgZpkhPS2ob3zkJJRwKGGwIHH2[ZJi\2Vib3[gOFUhdk1? NWnYU3BFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOFg3QDRpPkKzNVQ5Pjh2PD;hQi=>
H2009 M1r2WWNmdGxiVnnhZoltcXS7IFHzd4F6 M2naVlUxOCCwTR?= NX7MOGNoPzJiaB?= M3H0VWROW09? MljPdoV{fWy2czDpckBIOS:VLYDoZZNmKGGlY4XteYxifGmxbjDjc41jcW6nZDD3bZRpKE2NLUG3O|U> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF2OE[4OEc,OjNzNEi2PFQ9N2F-
Su.86.86 NX25WZhFS2WubDDWbYFjcWyrdImgRZN{[Xl? MnfYOVAxKG6P NFfKNoY4OiCq MXjEUXNQ M4DzZZJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 NEjuWmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G0PFY5PCd-MkOxOFg3QDR:L3G+
HRE M{HhdWNmdGxiVnnhZoltcXS7IFHzd4F6 NHH1fpY2ODBibl2= MkfkO|IhcA>? MXXEUXNQ M{\pepJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 MonTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNEi2PFQoRjJ|MUS4Olg1RC:jPh?=
HMEC Mo[4R4VtdCCYaXHibYxqfHliQYPzZZk> NYrMXW5rPTByIH7N M3GzcVczKGh? MWDEUXNQ NXjpNVRKemW|dXz0d{BqdiCJMT;TMZBp[XOnIHHjZ5VufWyjdHnvckBkd22kaX7l[EB4cXSqIF3LMVE4PzV? M37pXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUS4Olg1Lz5{M{G0PFY5PDxxYU6=
U2OS  NXXwWFh5TnWwY4Tpc44hSXO|YYm= NILhfZQzKML3TR?= MnLtNE0zPCCq M1zkVYlv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczFiYYSgd4VzcW6nIEO0OUBifCCkb4ToJINwdmOnboTyZZRqd26|IHHzJIViemy7IHHzJFIhcCCjZoTldkBi\G2rbnnzeJJifGmxbh?= M3vub|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUO3NVQ4Lz5{MkmzO|E1PzxxYU6=
U2OS  M{PLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\vXHU5OC1zMDFCuW0> Mmj5NlQwPDhiaB?= NFfzSmVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MnvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7M{exOFcoRjJ{OUO3NVQ4RC:jPh?=
U937 NWGx[|VbTnWwY4Tpc44hSXO|YYm= MmOzNVAxNTVyMDDuUS=> Mnv4OEBpyqB? NHzvWINl\WO{ZXHz[ZMhfGinIHP5eIFz[WKrbnWtbY5lfWOnZDDDbIsyKGG3dH;wbI9{eGixconsZZRqd25iYYSgV4VzOjl4wrDhcoQheHKndnXueJMhS2SlMkXBJIRwf26{ZXf1cIF1cW:w MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh4OUi2PUc,OjJ6Nkm4Olk9N2F-
U937 NEn5SZNHfW6ldHnvckBCe3OjeR?= NEjjfpUyODBibl2= M2XPSlQhcMLi M4nvPZJmfmW{c3XzJJRp\SCleYThdoFjcW6nLXnu[JVk\WRiaX7obYJqfGmxbjDv[uKhO0hvdHj5cYllcW6nIHnuZ49zeG:{YYTpc44hcW62bzDEUmE> NHHFToM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2PVg3QSd-MkK4Olk5Pjl:L3G+
U937 MnPySpVv[3Srb36gRZN{[Xl? NEHxXXYyODBvNUCwJI5O M{jWWFQhcMLi NUjWU2tIcW6mdXPld{BqdmO{ZXHz[YQheGixc4Doc5J6dGG2aX;uJI9nKEh{QWi= M2fOOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OE[5PFY6Lz5{Mki2PVg3QTxxYU6=
HL-60 MkDmRZBweHSxc3nzJGF{e2G7 MmrlN|AwOTByL{OwNEBvVQ>? M3rHTlI1KGh? MVTEUXNQ MoXr[Y5p[W6lZYOgZ5l1[XKjYnnu[U1qdmS3Y3XkJIFxd3C2b4Ppdy=> MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Nkm4OlkoRjJ{OE[5PFY6RC:jPh?=
ML-1 MlfvRZBweHSxc3nzJGF{e2G7 MVmyOU82OC9zMECgcm0> NImyVIkzPCCq NHPIR2NFVVOR NILRfpBmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{ NWXK[lh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
HCT116 MnzhSpVv[3Srb36gRZN{[Xl? NWLLcY85OSEEtV2= NFjnc4kzPCCq NIrZfoVi[nKxZ3H0[ZMhd2ZiY3XscEBkgWOuZTDhdpJme3UEoB?= NXrCdpZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NVA2PjBpPkKyOVExPTZyPD;hQi=>
U2OS NX7mSYE3TnWwY4Tpc44hSXO|YYm= M33IWVEhyrWP M3;CV|I1KGh? MXPhZpJw\2G2ZYOgc4Yh[2WubDDjfYNt\SCjcoLld5TDqA>? M{TyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUGwOVYxLz5{MkWxNFU3ODxxYU6=
Sf9 M2q3VGZ2dmO2aX;uJIF{e2G7 NF7ibndKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzJxQ4njcIlvKEFiZYjwdoV{e2WmIHnuJIlve2WldDDT[lkh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbN|NRZS2DVGCgbY5kd3Kyb4LheIlwdiCrboTvJIJqd3SrbonsZZRm\CCqaYP0c45mKEhzIHHmeIVzKDFiaIKgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkG2JO69VS5? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB7NE[wO{c,OjFyOUS2NFc9N2F-
Assay
Methods Test Index PMID
Western blot p-chk1(ser345) / CDC25A Cyclin E / pY15-CDK / γH2AX 27690219 26595527
体内研究 相对于gemcitabine或SCH 900776单独给药,Gemcitabine给药30分钟后,4 mg/kg SCH 900776足以诱导γ-H2AX生物标志物,而8 mg/kg增强肿瘤药效动力学和退化响应。递增剂量的SCH 900776 (16 mg/kg和32 mg/kg)诱导肿瘤响应持续改进。重要的是,在BALB/c 小鼠体内,SCH 900776的剂量与强的生物标志物活化相关,而提高的肿瘤响应与gemcitabine对血液学指标增强的毒性无关。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
  • Animal Models: 皮下注射A2780 或 MiaPaCa2细胞的额雌性裸鼠
  • Dosages: ~50 mg/kg
  • Administration: 腹腔内注射

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% propylene glycol

5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 376.25
化学式

C15H18BrN7

CAS号 891494-63-6
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00779584 Completed Drug: MK-8776|Drug: Gemcitabine Hodgkin Disease|Lymphoma Non-Hodgkin|Neoplasms Merck Sharp & Dohme LLC October 17 2008 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

回答:
Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Tags: buy MK-8776|MK-8776 ic50|MK-8776 price|MK-8776 cost|MK-8776 solubility dmso|MK-8776 purchase|MK-8776 manufacturer|MK-8776 research buy|MK-8776 order|MK-8776 mouse|MK-8776 chemical structure|MK-8776 mw|MK-8776 molecular weight|MK-8776 datasheet|MK-8776 supplier|MK-8776 in vitro|MK-8776 cell line|MK-8776 concentration|MK-8776 nmr|MK-8776 in vivo|MK-8776 clinical trial|MK-8776 inhibitor|MK-8776 Cell Cycle inhibitor